Latest Candel Therapeutics News & Updates
See the latest news and media coverage for Candel Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of viral immunotherapies for cancer
candeltx.com- Headquarters
- Needham, United States
- Founded year
- 1999
- Company type
- Public company
- Number of employees
- 80–200
Last updated
Latest news about Candel Therapeutics
Company announcements
-
Candel Therapeutics presents phase 2 data for CAN-2409
Data shows 50% of NSCLC patients surviving beyond 24 months, supporting phase 3 trial initiation.
-
Candel Therapeutics hosts conference call on CAN-2409 data
The call on May 15 at 1:00 PM ET discusses phase 3 trial follow-up data presented at #AUA26, featuring company leaders and experts.
-
Candel Therapeutics announces commercialization agreement with EVERSANA
EVERSANA provides integrated services for potential U.S. launch of aglatimagene besadenovec in localized prostate cancer following Q4 2026 BLA submission.
-
Candel Therapeutics reports extended survival in NSCLC trial
50% of patients survived beyond 24 months with CAN-2409. Median OS reached 25.4 months. Phase 3 trial planned for Q2 2026.
Media coverage
-
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer...
-
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA...
-
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate ...
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
-
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
Track Candel Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Candel Therapeutics competitors & trending companies
Browse news for competitors to Candel Therapeutics and other trending companies.
Humane Genomics
Aura Biosciences
Oncopeptides
Imugene
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global